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Original Article
Objectives: The survival outcomes of antiretroviral treatment (ART) programs have not been systematically evaluated at the state lev-
el in India. This retrospective study assessed the survival rates and factors associated with survival among adult human immunodefi-
ciency virus (HIV)-infected patients in Andhra Pradesh, India.
Methods: The present study used data from 139 679 HIV patients aged ≥15 years on ART who were registered from 2007 to 2011 and 
were followed up through December 2013. The primary end point was death of the patient. Mortality densities (per 1000 person-
years) were calculated. Kaplan-Meier and Cox-regression models were used to estimate survival and explore the factors associated 
with survival.
Results: The overall median follow-up time was 16.0 months (2.0 months for the deceased and 14.0 months for those lost to follow-
up). Approximately 13.2% of those newly initiated on ART died during follow-up. Of those deaths, 56% occurred in the first three 
months. The crude mortality rate was 80.9 per 1000 person-years at risk. The CD4 count (adjusted hazard ratio [aHR],4.88; 95% confi-
dence interval [CI], 4.36 to 5.46 for <100 cells/mm3 vs. >350 cells/mm3), functional status (aHR, 3.05; 95% CI, 2.82 to 3.30 for bedrid-
den vs. normal), and body weight (aHR, 3.69; 95% CI, 3.42 to 3.97 for <45 kg vs. >60 kg) were strongly associated with the survival of 
HIV patients.
Conclusions: The study findings revealed that high mortality was observed within the first three months of ART initiation. Patients 
with poor baseline clinical characteristics had a higher risk of mortality. Expanded testing and counseling should be encouraged, with 
the goal of ensuring early enrollment into the program followed by the initiation of ART in HIV-infected patients.
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INTRODUCTION
Morbidity and mortality related to human immunodeficien-
cy virus (HIV) and acquired immunodeficiency syndrome 
(AIDS) remain a global public health concern. Worldwide, the 
estimated number of people living with HIV (PLHIVs) was near-
ly 34 million in 2010, a 17% increase from 2001 [1]. With over 
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one million people living with HIV or AIDS (PLHAs) in 2011, In-
dia has the third largest number of PLHAs in the world [2]. The 
national prevalence of HIV in adults (aged ≥15 years) in India 
is estimated to be 0.27% [2], with approximately 5-fold higher 
prevalence rates among high-risk groups, including males who 
have sex with male, female sex workers, and injecting drug us-
ers [3]. These population groups are considered important 
bridging populations for HIV transmission between high-risk 
and low-risk population groups [4]. The early initiation of anti-
retroviral treatment (ART) has been shown to enhance the sur-
vival of HIV-infected persons worldwide [5,6]. In early 2000, 
low-income and middle-income countries expanded access to 
ART through the three by five Initiative of the World Health Or-
ganization (WHO) [7]. According to the Joint United Nations 
Program on HIV/AIDS (UNAIDS) [8], approximately 300 000 
HIV-related deaths have been averted due to ART in Asia. In 
2004, the ART program in India was launched under the Na-
tional AIDS Control Program with the aim of providing free ART 
services to those with a CD4 count less than 250 or at an ad-
vanced stage of disease. At present, more than 450 ART centers 
provide free ART treatment across the country [9].
In 2007 ART services were scaled up, with new criteria for 
ART initiation (CD4 ≤200 cells/mm3 or HIV clinical stage III/IV 
irrespective of CD4 count, including coinfections such as tu-
berculosis), which resulted in more than seven million PLHIVs 
accessing ART in 2012 [10]. The ART initiation criteria were fur-
ther modified in 2009-2010 (to CD4 ≤250 cells/mm3) and 
2011-2012 (to CD4 ≤350 cells/mm3), as recommended by 
UNAIDS [2]. In addition to free treatment, PLHIVs are provided 
follow-up monitoring, screening for opportunistic infections, 
and counseling. According to ART guidelines, zidovudine +  
lamivudine (3TC) + nevirapine (NVP) is the preferred regimen 
of treatment for patients with a hemoglobin level >9 g/dL, 
and stavudine + 3TC + NVP is given to those with hemoglobin 
<9 g/dL. Efavirenz is substituted for nevirapine in those taking 
anti-tubercular drugs and those with nevirapine toxicity. De-
spite the considerable increase in the number of PLHAs in In-
dia accessing ART from 17% in 2007 to 52% in 2013, ART cov-
erage of people eligible for treatment is still low [2,11].
A recent retrospective cohort analysis from an ART center 
showed the mortality rate in one  year to be 7.7 deaths per 
100 patients, with >50% of the deaths occurring during the 
first three months after ART initiation [12]. A few studies have 
been conducted investigating the survival benefit of upscal-
ing ART in India. Although the findings demonstrated a higher 
mortality than that of developed countries, the survival rate of 
the patients increased and the rate of opportunistic infections 
decreased [12-15]. No state-level studies have yet been per-
formed in India focusing on the survival outcomes of upscal-
ing ART services. Therefore, the available evidence in the 
country regarding the survival outcomes of upscaling ART ser-
vices is limited, despite the large number of patients accessing 
ART through the National AIDS Control Program. Therefore, 
large scale state-level survival studies are needed to better 
understand the HIV control program and to identify priority 
areas within states for further policy making. This retrospec-
tive study explores the survival rates and the factors associat-
ed with survival among ART patients in Andhra Pradesh state, 
including Telengana, a newly created state (separated from 
Andhra Pradesh), one of the six high-prevalence states of India 
using the most recent available HIV surveillance data since the 
scaling-up of ART in this state.
METHODS
Study Settings 
Andhra Pradesh has the second highest HIV prevalence 
(0.75%) after Manipur among the six high HIV prevalence 
states, with an estimated 490 000 PLHIVs in 2011 [2]. As of De-
cember 2014, the state had 56 functional ART and 161 func-
tional ART linkage centers across 25 districts, as compared to 
24 ART centers and 21 ART linkage centers in 2007 [16,17]. Ac-
cording to the 2011 census, the population of Andhra Pradesh 
was 84 665 530 with a density of 308 persons/km2.
Study Participants
This study used retrospective data from a cohort of HIV-pos-
itive patients from 2007 to 2013. Data were extracted from the 
PLHA database from 51 ART centers, which incorporates infor-
mation that has been routinely collected by the program since 
2004. The database included information on treatment initia-
tion and follow-up of HIV-positive patients who visit ART cen-
ters. For every patient, the first follow-up visit was scheduled 
two weeks after the initiation of treatment, and thereafter, on 
a monthly basis, the medical records of every patient were up-
dated during each follow-up visit. The total eligible sample 
was 139 679 adult HIV-infected patients, who were followed 
up from 2007 to 2013 (Figure 1). The study participants includ-
ed all adult HIV-positive patients (aged 15 years and older) on 
ART, who were registered during January 2007 to December 
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2011 and initiated treatment before December 31, 2013. Par-
ticipants with a previous treatment history, without a date of 
ART initiation, and pediatric cases (aged 0-14 years) were ex-
cluded from the study.  
Ethical Statement
Approval to access the PLHA database was obtained from 
the National AIDS Control Organization, New Delhi, India. The 
personal identity of the patients was not accessed and confi-
dentiality was maintained.
Measures
Baseline data were collected on patients’ demographic and 
clinical characteristics. HIV program-related information was 
also gathered, including patients’ ART status, date of ART initi-
ation, follow-up status, and the date of their last visit to the 
ART center. 
Socio-demographic variables
The socio-demographic variables used in the analysis were 
age (<30 years, 30-45 years, and >45 years), education (illiter-
ate, primary, secondary, and college and above), employment 
status (self-employed and service), and marital status (single 
[including unmarried/widow/widower] and married/cohabi-
tating).
Clinical characteristics
Clinical characteristics at the time of ART initiation included 
body weight (kg), functional status, WHO clinical stage, CD4 T-
cell count (cells/mm3), and adherence to ART. The patient’s 
body weight at the time of ART initiation was categorized into 
three groups: <45 kg, 45-60 kg, and >60 kg. The functional 
status of the patient was recorded by the counselor at the time 
of ART initiation and categorized into three groups: normal, 
ambulatory, and bedridden during the past month. The WHO 
clinical stage was categorized into four groups (stage I, stage 
II, stage III, and stage IV), with stage IV considered to be the 
worst health condition that was assessed by health profession-
als at ART centers based on the load of clinical symptoms and 
infections, and recorded using the WHO clinical stage guide-
lines [18]. CD4 count was categorized as <100 cells/mm3, 101-
200 cells/mm3, 201-350 cells/mm3, and >350 cells/mm3, and 
adherence to ART was categorized as <95% and ≥95% [13].
The date of death for all HIV-infected patients who died 
from any cause during the study period while on ART was re-
corded. Patients who missed their follow-up visits for more 
than three months were considered lost to follow-up, and the 
date of the last registered follow-up visit was recorded as the 
date of loss to follow-up. HIV-infected patients on ART who 
were transferred to another ART center, were recorded as 
transferred-out cases, and their date of transfer was also re-
corded. Similarly, patients put on medical advice (due to some 
complications or any adverse effects) were recorded as being 
on medical advice and the date when this advice was given 
was also recorded.
Statistical Analysis
The follow-up time (months) was calculated from the date 
of initiation of ART to the date of death for patients who died, 
or the date of the last recorded visit for patients who were 
censored (alive until the end of the study period, lost to follow-
up, transferred out, or on medical advice). The primary end-
point of the study was death. Kaplan-Meier methods were 
used to estimate survival after ART initiation. Patients were 
stratified by different population subgroups. We used the Wil-
coxon log-rank test to assess the statistical differences be-
tween subgroups. Mortality density across the study period 
was estimated as the number of deaths per 1000 person-years 
Figure 1. Flow chart of study sample determination. HIV, hu-
man immunodeficiency virus; ART, antiretroviral therapy.
Total 310 497 HIV-positive
patients registered at ART
centers in Andhra Pradesh
between 2007 and 2011
293 560 HIV-positive
patients registered as adults
(age ≥15 y)
180 022 HIV-positive
patients started ART treatment
139 679 HIV-positive cases on ART were 
included in the data analysis
Pediatric cases
(n=16 937)
Not on ART
(n=113 538)
Date of ART initiation 
unknown
(n=40 343)
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of ART initiation to understand the pattern of deaths.
All baseline demographic and clinical characteristics were 
used as independent variables in the analysis. The proportion-
al hazards assumption was tested using the Schonefild residu-
als plot, and all the predictor variables satisfied the criterion of 
being asymptotic. The widely accepted Cox-proportional haz-
ard regression model was applied to identify factors associat-
ed with mortality [3,13,14]. The univariate Cox regression 
analysis was used to estimate the unadjusted hazard ratios 
(HRs). Stepwise (backward logistic regression) multivariate Cox 
regression analysis (including all predictor variables) was ap-
plied to estimate the adjusted HRs with 95% confidence inter-
vals (CIs). The probability for the stepwise regression analysis 
was 0.05 for entry of the variables and 0.10 for removal of the 
variables from the model. A sensitivity analysis called ‘the 
worst-case scenario’ was also performed, in which all patients 
lost to follow-up were classified as deceased immediately after 
their last contact with the center and presented separately. All 
the tests were two-sided and the criterion for statistical signifi-
cance was set at p-value<0.05. The data were analyzed using 
Stata version 13.0 (StataCorp, College Station, TX, USA) and 
SPSS version 22.0 (IBM Corp., Armonk, NY, USA).
RESULTS 
The baseline demographic and clinical characteristics of 
adult HIV-positive patients on ART are summarized in Table 1. 
The mean age of patients at the start of ART was 34.9±9.2 
years, 54.7% were male, 45.2 had completed formal educa-
tion, 68.1% were married or had a live-in partner, and 74.0% 
voluntarily enrolled in the HIV control program. The median 
baseline CD4 count was 172 cells/mm3 and the medium body 
weight was 46 kg. Approximately 32.1% of patients were re-
corded as being in WHO clinical stage III or IV, and 61.1% of 
them were adherent (≥95%) to ART treatment.
The overall median follow-up time for all patients was 16.0 
months or 1.3 years (interquartile range, 0.3 to 2.8 years). The 
median follow-up time for the deceased was 2.0 months, 14.0 
months for those lost to follow-up, and 5.0 months for those 
who were transferred out, which were lower than the median 
Table 1. Baseline demographic and clinical characteristics of HIV-positive patients on ART by number of cases and number of 
deaths, Andhra Pradesh, 2007-2011
Background characteristics
Year of ART registration
Combined
2007 2008 2009 2010 2011
Total number of patients who initiated treatment 22 514 29 827 30 321 32 031 24 986 139 679
Voluntary enrolled in the HIV program 16 071 (71.4) 22 313 (74.8) 22 780 (75.1) 23 787 (74.3) 18 423 (73.7) 103 374 (74.0)
Demographic information
   Age  (mean±SD) 33.5±8.6 34.1±8.7 34.9±9.1 35.6±9.4 36.3±9.7 34.9±9.2
   Male 9899 (44.0) 13 524 (45.3) 14 037 (46.3) 14 910 (46.5) 11 409 (45.7) 63 779 (54.7)
   Formally educated 11 622 (51.6) 13 818 (46.3) 12 862 (42.4) 13 794 (43.1) 11 094 (44.4) 63 190 (45.2)
   Employed 17 307 (76.9) 19 774 (66.3) 17 002 (56.1) 15 695 (49.0) 12 793 (51.2) 82 571 (59.1)
   Married or with a partner 15 562 (69.1) 20 237 (67.8) 20 594 (67.9) 21 719 (67.8) 17 058 (68.3) 95 170 (68.1)
Clinical information at the time of ART initiation
   Median CD4 cell count (IQR) 155 (88, 223) 163 (99, 227) 177 (106, 243) 182 (108, 247) 182 (105, 256) 172 (102, 240)
   WHO clinical stage III or IV 8502 (37.8) 10 461 (35.1) 9326 (30.8) 10 497 (32.8) 6035 (24.2) 44 821 (32.1)
   Heterosexual mode of HIV   transmission 19 347 (85.9) 28 354 (95.1) 29 354 (96.8) 30 687 (95.8) 23 618 (94.5) 131 360 (94.0)
   Body weight <45 kg 7497 (33.3) 9946 (33.3) 10 449 (34.5) 10 710 (33.4) 8132 (32.5) 46 734 (33.5)
   Functionally well for work 13 016 (57.8) 23 208 (77.8) 24 474 (80.7) 25 083 (78.3) 19 197 (76.8) 104 978 (75.2)
   Adherent (≥95%) to treatment 12 966 (57.6) 18 863 (63.2) 19 689 (64.9) 19 948 (62.3) 13 856 (55.5) 85 322 (61.1)
Follow up status as of  December 31, 2013
   Surviving 11 934 (53.0) 16 967 (56.9) 19 033 (62.8) 22 537 (70.4) 19 048 (76.2) 89 519 (64.1)
   Died 3192 (14.2) 4527 (15.2) 4010 (13.2) 3992 (12.5) 2673 (10.7) 18 394 (13.2)
   Lost to follow-up 3835 (17.0) 4720 (15.8) 3991 (13.2) 2601 (8.1) 1475 (5.9) 16 624 (11.9)
   Transferred out 3553 (15.8) 3613 (12.1) 3287 (10.8) 2899 (9.1) 1790 (7.2) 15 142 (10.8)
Values are presented as number (%).
HIV, human immunodeficiency virus; ART, antiretroviral therapy; SD, standard deviation; IQR, interquartile range; WHO, World Health Organization.
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follow-up time for survivors (23.0 months). The overall survival 
probability among adult HIV-positive patients decreased over 
follow-up (Figure 2), and the mean survival over the study pe-
riod was found to be 70.4 months (95% CI, 70.2 to 70.6 
months). The survival probabilities of patients at three months, 
six months, one year, two years, and five years were 96.5%, 
94.8%, 92.0%, 88.9%, and 87.9%, respectively.
As seen in Table 2, of the 18 394 patients who died, 10 305 
(56.0%) died within three months of initiating treatment. The 
study cohort contributed a total of 227 315.9 person-years at 
risk during the study period. The overall mortality density was 
80.9 per 1000 person-years at risk. The mortality rate was 
higher among patients who were older (>45 years), male, 
with a low baseline body weight (<45 kg), at baseline WHO 
clinical stage III or IV, had a baseline ambulatory or bedridden 
functional status, a CD4 count less than 200 cells/mm3, and 
initiated treatment according to older ART initiation criteria (≤
200 cells/mm3 or ≤250 cells/mm3). The effectiveness of ART in 
the HIV control program was assessed using the CD4 criteria 
for ART initiation as the indicator variable. The chances of sur-
vival of HIV-positive patients significantly improved (p<0.001) 
at every time point as the CD4 criterion for ART initiation in-
creased.
Table 3 shows a stratified analysis of factors associated with 
survival among adult HIV-infected patients. Multivariable anal-
ysis was used to calculate the adjusted hazard ratios for these 
variables. The risk of mortality was significantly higher among 
patients in the older age group (age >45 years: HR, 1.41; 95% 
CI, 1.34 to1.48). As body weight decreased, the risk of mortality 
increased, with a risk 3.69 times greater among patients less 
Figure 2. Kaplan-Meier survival plots for overall survival (A), age groups (B), sex (C), baseline CD4 counts (D), baseline body 
weight (E), baseline WHO clinical stage (F), adherence to HIV treatment (G), baseline functional status (H), and year of CD4 
change criterion (I) of HIV-infected individuals after ART initiation in Andhra Pradesh state from 2007 to 2013. HIV, human immu-
nodeficiency virus; ART, antiretroviral therapy; WHO, World Health Organization.
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Table 2. Mortality density (per 1000 person-years) of HIV-positive patients on ART by selected baseline background characteristics
Background characteristics    No. of patients No. of deaths (%)
No. of deaths
in 6 mo (%)
Total person-
years at risk
Mortality density 
per 1000 person-
years at risk
Age (y)
   <30 40 666 4342 (10.7) 2907 (23.4) 68 298.5 63.6
   30-45 82 146 11 241 (13.7) 7651 (61.5) 132 878.0 84.6
   >45 16 867 2811 (16.7) 1882 (15.1) 25 874.0 108.6
Sex
   Male 75 900 12 115 (16.0) 8189 (65.8) 124 102.8 97.6
   Female 63 779 6279 (9.8) 4251 (34.2) 103 093.4 60.9
Baseline body weight (kg)
   <45 46 734 8554 (18.3) 6191 (49.8) 75 350.8 113.5
   45-60 60 957 6247 (10.2) 3830 (30.8) 99 878.0 62.5
   >60 13 343 802 (6.0) 416 (3.3) 21 812.5 36.8
   Missing1 18 645 2791 (15.0) 2003 (16.1) 28 691.5 97.3
Baseline WHO clinical stage
   Stage I 21 252 2079 (9.8) 1379 (11.1) 31 341.4 66.3
   Stage II 54 284 6328 (11.7) 4110 (33.0) 87 030.8 72.7
   Stage III 40 967 6348 (15.5) 4336 (34.9) 69 138.6 91.8
   Stage IV 3854 1065 (27.6) 827 (6.6) 6677.1 159.5
   Missing1 19 322 2574 (13.3) 1788 (14.4) 32 298.3 79.7
Baseline functional status
   Normal 104 978 12 136 (11.6) 7838 (63.0) 167 807.3 72.3
   Ambulatory 15 089 3646 (24.2) 2651 (21.3) 27 489.6 132.6
   Bedridden 1686 804 (47.7) 682 (5.5) 2567.9 313.1
   Missing1 17 926 1808 (10.1) 1269 (10.2) 28 185.6 64.1
Baseline CD4 count (cells/mm3) 
   ≤100 27 555 5649 (20.5) 4144 (33.3) 47 197.1 119.7
   101-200 40 586 5124 (12.6) 3307 (26.6) 68 793.3 74.5
   201-250 19 488 1544 (7.9) 885 (7.1) 30 152.8 51.2
   251-350 14 211 813 (5.7) 445 (3.6) 20 659.2 39.4
   351-500 5521 205 (3.7) 90 (0.7) 8091.9 25.3
   >500 4508 126 (0.7) 56 (0.5) 6548.2 19.2
   Missing1 27 810 4933 (17.7) 3513 (28.2) 44 584.1 110.6
Year of ART initiation according to CD4 criteria (cells/mm3)
   2007-2008 (≤200) 43 516 7061 (16.2) 4662 (37.5) 92 399.0 76.4
   2009-2011 (≤250) 84 704 10 902 (12.9) 7452 (59.9) 106 275.3 102.6
   2012 onwards (≤350) 11 459 431 (3.8) 326 (2.6) 8406.1 51.3
Adherence to ART treatment (%)
   ≥95 85 322 4785 (5.6) 707 (5.7) 129 405.0 37.0
   <95 10 252 976 (9.5) 170 (1.4) 15 036.3 64.9
   Missing1 44 105 12 633 (28.6) 11 563 (92.9) 33 446.3 377.7
Total patients 139 679 18 394 (13.2) 12 440 (67.6) 227 315.9 80.9
HIV, human immunodeficiency virus; ART, antiretroviral treatment; WHO, World Health Organization.
1Missing data in the variable is categorized in a separate category that defined as ‘missing’.
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than 45 kg (95% CI, 3.42 to 3.97) than among those weighing 
more than 60 kg. Patients at WHO clinical stage IV were at a 
higher risk (HR, 1.45; 95% CI, 1.36 to 1.56) than those at stage I 
or II. Patients with a baseline bedridden functional status were 
3.05 times more likely to die than patients with normal func-
tional status at the start of treatment (95% CI, 2.82 to 3.30). The 
Table 3. Univariable and multivariable hazard ratios with 95% confidence intervals of mortality according to baseline back-
ground characteristics using a Cox proportional hazard model
Predictors1 of 
   mortality
Male Female Combined
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 
Age (y) 
   <30 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   30-45 1.07 (1.02, 1.12)* 1.14 (1.09, 1.20)* 1.25 (1.19, 1.32)* 1.22 (1.16, 1.29)* 1.29 (1.24, 1.33)* 1.18 (1.14, 1.23)*
   >45 1.25 (1.18, 1.33)** 1.32 (1.24, 1.40)* 1.69 (1.56, 1.84)** 1.57 (1.45, 1.71)** 1.61 (1.54, 1.69)** 1.41 (1.34, 1.48)**
Baseline body weight 
   (kg)
   <45 5.20 (4.79, 5.64)*** 4.04 (3.72, 4.39)*** 3.31 (2.79, 3.93)*** 2.68 (2.22, 3.23)*** 3.43 (3.20, 3.69)*** 3.69 (3.42, 3.97)***
   45-60 2.16 (1.99, 2.34)*** 1.92 (1.77, 2.08)** 1.17 (0.98, 1.40) 2.50 (2.11, 2.96)** 1.79 (1.66, 1.92)** 1.74 (1.62, 1.88)**
   >60 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Missing2 3.33 (3.05, 3.64)*** 3.09 (2.81, 3.41)*** 2.98 (2.49, 3.56)*** 1.07 (0.89, 1.28) 2.95 (2.72, 3.19)*** 3.14 (2.88, 3.42)***
Baseline WHO clinical 
   stage
   Stage I or II 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Stage III 1.32 (1.27, 1.38)** 1.09 (1.04, 1.13)* 1.44 (1.36, 1.52)** 1.13 (1.06, 1.20)* 1.40 (1.36, 1.45)** 1.10 (1.07, 1.14)*
   Stage IV 2.41 (2.23, 2.61)*** 1.33 (1.22, 1.45)** 3.47 (3.11, 3.87)*** 1.78 (1.57, 2.00)** 2.84 (2.66, 3.03)*** 1.45 (1.36, 1.56)**
   Missing2 1.26 (1.20, 1.33)** 1.27 (1.18, 1.37)** 1.30 (1.20, 1.40)** 1.29 (1.17, 1.42)** 1.29 (1.23, 1.34)** 1.28 (1.21, 1.36)*
Baseline FS
   Normal 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Ambulatory 2.08 (1.98, 2.17)** 1.61 (1.53, 1.69)** 2.43 (2.28, 2.69)** 1.76 (1.65, 1.88)** 2.23 (2.15, 2.31)** 1.66 (1.60, 1.73)**
   Bedridden 5.06 (4.63, 5.52)*** 2.87 (2.60, 3.16)*** 7.26 (6.42, 8.31)*** 3.50 (3.05, 4.01)*** 5.90 (5.50, 6.34)*** 3.05 (2.82, 3.30)***
   Missing2 0.97 (0.92, 1.04) 0.67 (0.62, 0.73)* 1.01 (0.93, 1.10) 0.64 (0.57, 0.71)* 0.99 (0.94, 1.04) 0.66 (0.62, 0.71)*
Baseline CD4 count 
   (cells/mm3)
   ≤100 6.60 (5.74, 7.59)*** 4.62 (4.02, 5.32)*** 8.04 (6.69, 9.65)*** 5.35 (4.44, 6.44)*** 7.32 (6.55, 8.18)*** 4.88 (4.36, 5.46)***
   101-250 3.63 (3.16, 4.17)*** 3.06 (2.66, 3.52)*** 3.51 (2.92, 4.21)*** 2.94 (2.44, 3.53)*** 3.63 (3.25, 4.05)*** 3.02 (2.70, 3.38)***
   251-350 2.00 (1.69, 2.35)** 1.92 (1.63, 2.26)** 1.97 (1.60, 2.43)** 2.06 (1.67, 2.54)** 1.96 (1.72, 2.23)** 1.96 (1.73, 2.23)**
   >350 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Missing2 6.16 (5.35, 7.08)*** 4.44 (3.86, 5.11)*** 6.06 (5.04, 7.28)*** 4.42 (3.67-5.32)*** 6.19 (5.54, 6.92)*** 4.45 (3.98, 4.98)***
Year of ART initiation 
    according to CD4 
criteria (cells/mm3)
   2007-2008 (≤200) 2.90 (2.56, 3.30)*** 1.90 (1.67, 2.16)** 3.54 (3.04, 4.12)*** 2.08 (1.78, 2.44)** 3.37 (3.05, 3.71)*** 1.97 (1.79, 2.18)**
   2009-2011 (≤250) 2.37 (2.10, 2.70)*** 1.65 (1.45, 1.87)** 2.77 (2.38, 3.22)*** 1.78 (1.52, 2.07)** 2.67 (2.43, 2.94)*** 1.71 (1.55, 1.88)**
   2012 onwards 
      (≤350)
1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Adherence to ART (%)
   <95 1.85 (1.70, 2.01)** 1.83 (1.69, 1.99)** 1.61 (1.42, 1.82)** 1.59 (1.41, 1.80)** 1.78 (1.66, 1.91)** 170 (1.65, 1.90)**
   ≥95 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Missing2 15.08 (14.42, 15.77)*** 14.87 (14.21, 15.56)*** 15.95 (15.02, 16.94)*** 16.26 (15.29, 17.27)*** 15.57 (15.01, 16.14)*** 15.58 (15.03, 16.16)***
Values are presented as hazard ratio (95% confidence interval).
WHO, World Health Organization; ART, antiretroviral treatment; FS, functional status. 
1Adjusted for education, marital status and employment.
2Missing data in the variable is categorized in a separate category that defined as ‘missing’.
*p<0.05, **p<0.01, ***p<0.001.
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likelihood of death among those with a baseline CD4 count of 
≤100 cells/mm3 increased 4-fold (HR, 4.88; 95% CI, 4.36 to 
5.46), and increased 3.02 times (95% CI, 2.70 to 3.38) when the 
CD4 count was 101-250 cells/mm3, in comparison to those with 
a CD4 count >350 cells/mm3. Moreover, the risk of mortality 
was nearly 2-fold greater (HR, 1.97; 95% CI, 1.79 to 2.18) in pa-
tients with the older CD4 treatment initiation criteria (≤200 
cells/mm3) and 1.70 times greater (95% CI, 1.65 to 1.90) in non-
adherent (<95%) patients than in adherent (≥95%) patients.
Similarly, Table 4 presents adjusted stratified risks under a 
worst-case scenario assumption (sensitivity analysis) that all 
patients lost to follow-up died immediately after discontinu-
ing their treatment. A similar pattern to the real-case scenario 
in Table 3 emerged in the risk factors. Older age groups, lower 
Table 4. Multivariable adjusted hazard ratios of mortality with 95% confidence intervals according to baseline background char-
acteristics using a Cox proportional hazard model under the worst-case-scenario assumption
Predictors1 of mortality Male Female Combined
Age (y)
   <30 1.00 (reference) 1.00 (reference) 1.00 (reference)
   30-45 1.04 (0.99, 1.07) 1.03 (0.99, 1.06) 1.07 (1.05, 1.10)*
   >45 1.17 (1.11, 1.22)** 1.13 (1.07, 1.21)** 1.22 (1.18, 1.26)**
Baseline body weight (kg)
   <45 1.68 (1.60, 1.77)*** 1.40 (1.26, 1.55)** 1.44 (1.38, 1.50)***
   45-60 1.21 (1.15, 1.27)** 1.31 (1.20, 1.44)** 1.15 (1.10, 1.20)**
   >60 1.00 (reference) 1.00 (reference)
   Missing2 1.53 (1.43, 1.63)*** 1.03 (0.94, 1.13) 1.46 (1.39, 1.55)***
Baseline WHO clinical stage
   Stage I or II 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Stage III 1.16 (1.13, 1.20)** 1.25 (1.21, 1.30)** 1.21 (1.18, 1.24)**
   Stage IV 1.28 (1.19, 1.38)** 1.54 (1.41, 1.70)*** 1.39 (1.32, 1.47)**
   Missing2 1.12 (1.07, 1.19)* 1.01 (0.94, 1.08) 1.07 (1.02, 1.12)*
Baseline functional status
   Normal 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Ambulatory 1.13 (1.08, 1.17)* 1.10 (1.05, 1.16)* 1.13 (1.09, 1.16)*
   Bedridden 1.63 (1.49, 1.78)*** 1.73 (1.54, 1.96)*** 1.69 (1.57, 1.81)***
   Missing2 0.53 (0.50, 0.57)* 0.49 (0.46, 0.53)* 0.51 (0.49, 0.54)*
Baseline CD4 count (cells/mm3)
   ≤100 1.74 (1.61, 1.89)*** 1.50 (1.38, 1.63)** 1.64 (1.55, 1.74)***
   101-250 1.67 (1.55, 1.81)** 1.52 (1.39, 1.65)** 1.63 (1.54, 1.73)***
   251-350 1.37 (1.27, 1.48)** 1.25 (1.16, 1.36)** 1.32 (1.25, 1.40)**
   ≥351 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Missing2 1.06 (0.97, 1.17) 1.08 (0.98, 1.18) 1.07 (0.99, 1.14)
Year of ART initiation according to CD4 criteria (cells/mm3)
   2007-2008 (≤200) 1.85 (1.68, 2.03)*** 1.69 (1.54, 1.86)*** 1.82 (1.70, 1.94)***
   2009-2011 (≤250) 1.65 (1.50, 1.81)** 1.54 (1.41, 1.69)** 1.63 (1.52, 1.74)**
   2012 onwards (≤350) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Adherence to ART (%)
   <95 1.35 (1.28, 1.43)** 1.22 (1.18-1.31)** 1.22 (1.18, 1.31)**
   ≥95 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Missing2 9.10 (8.81, 9.40)***  8.73 (8.41, 9.07)***  9.07 (8.85, 9.30)***
Values are presented as adjusted hazard ratio (95% confidence interval). 
ART, antiretroviral therapy; WHO, World Health Organization.
1Adjusted for education, marital status and employment.
2Missing data in the variable is categorized in a separate category that defined as ‘missing’.
*p<0.05, **p<0.01, ***p<0.001.
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body weight, poor clinical stage and functional status, lower 
CD4 counts, older criteria for treatment initiation, and poor 
adherence were significantly associated with an elevated risk 
of mortality.
DISCUSSION
This 7-year retrospective cohort study found a high mortali-
ty rate within three months of ART initiation (mortality density 
of 396.5 per 1000 person-years at risk; 95% CI, 387.4 to 405.5) 
among HIV-positive patients in Andhra Pradesh, in agreement 
with other studies conducted in resource-limited settings [3, 
13,14,19]. The main predictors of mortality among adult HIV-
positive patients on ART were being in the oldest age group, 
male sex, a low baseline body weight, poor baseline functional 
status, a poor baseline WHO clinical stage, a low baseline CD4 
count, and poor ART adherence (<95%). In the present study, 
13.6% of the adult HIV-positive patients on ART died, which is 
somewhat higher than the overall death rate (7.5%) observed 
in the ART program in Andhra Pradesh as of 2012 [2]. The 
cause of death was not investigated in this study; however, it 
is well-known that opportunistic infections are a major cause 
of mortality among HIV-positive individuals. In Andhra 
Pradesh and India, the most prevalent opportunistic infections 
among HIV-positive individuals are tuberculosis, candidiasis, 
and cryptosporidiosis [20].
The overall mortality reported in this study is higher than 
has been found in developed countries [21], but is in line with 
results from developing countries [15]. This may reflect poor 
participation of HIV-positive patients in the ART program in 
Andhra Pradesh. Similar to other studies [12,15], mortality was 
highest in the first three months after ART initiation. The poor 
outcomes in the initial few months after ART initiation might 
be due to delayed diagnosis and/or treatment, and explained 
by the fact that 60.5% of patients had advanced disease (CD4 
count <200 cells/mm3) and 37.2% of patients had advanced 
clinical symptoms (WHO clinical stage III or IV) at the time of 
treatment initiation. Several factors such as HIV-related stigma 
and discrimination [22] may have played a vital role in delay-
ing diagnosis and/or treatment. Moreover, the lack of proper 
screening diagnostic facilities for opportunistic infections and 
the limited availability of prophylaxis may have also increased 
mortality [19,21]. Advanced clinical stage (stage IV) is strongly 
linked with high mortality during the initial months of treat-
ment [23]. Findings from other countries similarly indicate that 
the effectiveness of ART in reducing mortality and increasing 
survival among HIV-infected patients may depend on ART ad-
herence, quality of services, and the clinical characteristics of 
patients [24,25].
The finding of this study that male HIV-positive patients had 
a higher risk of mortality than female patients is similar to 
what has been reported in other studies [3,21,24,26]; however, 
some previous studies [19,27] reported no significant associa-
tion between sex and mortality, but rather explained differ-
ences in terms of variations in the accessibility and utilization 
of health services. Moreover, late reporting at ART centers un-
less one is experiencing extreme HIV-related symptoms might 
be more common among male than female patients [24]. 
Stigma and discrimination, economic responsibility, risk be-
haviors and guilt associated with visiting sex workers, and 
masculine norms of being strong and healthy may be barriers 
to males accessing early testing and treatment.
In Andhra Pradesh, while twice the number of male than fe-
male HIV-infected persons were registered in integrated coun-
seling and testing centers in 2013, there were only 10% more 
male than female ART recipients in Andhra Pradesh [16]. This 
suggests that female patients tend to enroll more frequently 
than males in ART services, and additionally, they may have 
initiated early treatment due to linkage between the commu-
nity-based prevention of parent-to-child transmission (PPTCT) 
and the HIV treatment and care program. Providing PPTCT 
services at the community level has considerably increased 
their utilization by pregnant females, and may have encour-
aged females to determine their HIV status and start early 
treatment through awareness and counseling services [28,29].
The positive association between low baseline body weight 
and mortality documented in the present study is similar to 
findings of other studies that have found low body weight or 
body mass index to be significantly associated with high mor-
tality [24,25]. Low body weight could be a proxy marker for 
advanced disease (low CD4 and poor clinical stage) and a risk 
factor for opportunistic infections like tuberculosis [30]. Low 
body weight is associated with malnutrition, poor immunity, 
and poor living standards, which could also result in an in-
creased risk of mortality. Our finding that patients at an ad-
vanced WHO clinical stage (stage III or IV) had a higher risk of 
mortality than those at stage I or II is supported by several 
studies in other countries [23-25,28]. Adult HIV-positive pa-
tients who were bedridden during the past month had higher 
risk of mortality than patients with normal baseline functional 
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status at treatment initiation, as has been reported in other 
studies [3,21,30,31]. Bedridden functional status and being at 
clinical stage III or IV at ART initiation reflects the worst health 
condition of patients, and therefore, the combined effect of 
these clinical conditions could lead to mortality. These find-
ings suggest that patients died mainly due to late initiation of 
ART, when their health conditions were at their worst. 
This study shows that survival has improved significantly ac-
cording to changes in the CD4 criteria for ART initiation over 
the study period, suggesting that this criterion plays an impor-
tant role in affecting the mortality of HIV-positive patients 
[8,10]. Moreover, the baseline CD4 count was significantly as-
sociated with mortality in this study, which is consistent with 
previous studies [14,21,32]. A study in South Korea [32] showed 
that patients with a CD4 count of <200 cells/mm3 had mortali-
ty rates approximately 5 times higher than those with a CD4 
count ≥500 cells/mm3. Another study in Tanzania [27] found a 
higher likelihood of mortality among patients with a CD4 
count <200 cells/mm3 than among patients with a CD4 count 
≥200 cells/mm3. In the current study, poor adherence to ART 
(<95%) was also significantly associated with a higher risk of 
mortality. This finding is supported by a study conducted in 
Jharkhand [13] that showed a 3-fold higher risk of mortality 
among non-adherent patients (<95%).
The main strength of this study is that it documented ART 
program outcomes across the entire state of Andhra Pradesh, 
and hence the findings are applicable to other regions with a 
similar cultural and ecological context outside Andhra Pradesh. 
This study used routine treatment program data, which is a 
cost-effective approach that used well-monitored data. How-
ever, the results should be interpreted in light of certain limita-
tions. This study did not include information on the cause of 
death, the baseline treatment regimen, and opportunistic in-
fections in the study population. Although these details are 
routinely entered in the ART registers, due to incomplete infor-
mation in the online database, we were unable to include this 
data in the analysis. Moreover, the mortality outcomes of cases 
lost to follow-up in this study were not known; these cases 
may have been at higher risk of death, as shown in a meta-
analysis of studies in resource-limited settings that reported 
that on average 46% of traced patients lost to follow-up on 
ART had died [33].
The findings of this study provide critical insights for design-
ing effective and efficient HIV treatment, care, and support 
programs. Our findings show that the mortality rate among 
adult HIV-positive patients was high, and that the majority of 
deaths occurred within three months of ART initiation. Pa-
tients should be encouraged to be tested early for HIV, and 
those who test positive should be encouraged to initiate early 
treatment. Major efforts are required not only to trace those 
who are lost to follow-up but to initiate mechanisms to trace 
these patients early, when they have missed their monthly 
dose of treatment.
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